Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene expression in the bladder carcinoma rat model.

Ilana Ariel1, Suhail Ayesh, Ofer Gofrit

  • 1Department of Pathology, Hadassah-Hebrew University Medical Center, Hadassah University Hospital, Mount Scopus, PO Box 24035, Jerusalem IL-91240, Israel.

Molecular Carcinogenesis
|September 21, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ureteral obstruction caused by migration of a renal embolization coil 25 years after blunt renal trauma.

Urology case reports·2026
Same author

Case Report: A potential novel treatment for drug-induced acute interstitial nephritis: Benralizumab.

Frontiers in immunology·2025
Same author

Nodal Spread Prediction in Human Oral Tongue Squamous Cell Carcinoma Using a Cancer-Testis Antigen Genes Signature.

International journal of molecular sciences·2025
Same author

[PREVALENCE OF BENIGN PROSTATIC HYPERPLASIA IN SPINA BIFIDA PATIENTS].

Harefuah·2025
Same author

[PROSTATE ARTERY EMBOLIZATION FOR WEANING OF INDWELLING URINARY CATHETER].

Harefuah·2025
Same author

Interactions at sea: on the microbiome life-cycle and biogeochemical processes.

History and philosophy of the life sciences·2025

This study shows N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)-induced rat bladder cancer mirrors human disease. Gene expression in this model supports its use for testing new gene therapies for bladder cancer.

Area of Science:

  • Oncology
  • Translational Medicine
  • Molecular Biology

Background:

  • N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) induces rat bladder carcinoma, a model for human transitional cell carcinoma (TCC).
  • Understanding gene expression in this model is crucial for developing targeted therapies.

Purpose of the Study:

  • To evaluate the BBN-induced rat bladder carcinoma model for its applicability in studying novel therapeutic modalities, especially gene therapy.
  • To analyze the expression of H19 gene, insulin-like growth factor 2 (Igf2) transcripts (promoters P2 and P3), and telomerase subunits in the BBN-induced tumors.
  • To confirm the model's relevance by comparing gene expression profiles with human bladder carcinoma.

Main Methods:

  • Administration of BBN in drinking water to Wistar rats for up to 30 weeks to induce papillary TCC.

Related Experiment Videos

  • Morphological staging of tumors according to modern human bladder carcinoma terminology.
  • Quantitative analysis of H19, Igf2 (P2, P3), and telomerase subunit gene expression.
  • Utilizing cDNA expression arrays (Clontech) to identify additional differentially expressed tumor-specific genes.

    • Main Results:

    • Significant upregulation of H19 gene, Igf2 transcripts, and telomerase subunits was detected in rat bladder tumors after 30 weeks of BBN exposure.
    • These molecular findings in the rat model are consistent with previously observed patterns in human bladder cancer.
    • Additional tumor-specific genes with altered expression in human bladder carcinoma were identified using cDNA expression arrays.

    Conclusions:

    • The BBN-induced rat bladder cancer model exhibits significant morphological, biological, and molecular parallels to human bladder cancer.
    • This model serves as a valuable platform for investigating novel therapeutic interventions, including gene therapy, for bladder cancer.
    • The observed gene expression patterns reinforce the utility of this animal model for preclinical studies in bladder cancer therapeutics.